Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study

This study investigated the impact of two common treatments for Seasonal Affective Disorder (SAD) on patients' quality of life (QoL).

The interventions tested were:

1. **High-dose light therapy:** Patients received 10,000 lux light treatment daily, combined with a placebo capsule.

2. **Antidepressant medication:** Patients received 20 mg of fluoxetine (a selective serotonin reuptake inhibitor, or SSRI), combined with a low-dose "placebo light" treatment of 100 lux.

The comparators were these two treatment conditions against each other. The study aimed to see if one treatment was superior to the other in improving QoL, or if both were equally effective.

The primary outcome measures were:

**Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q):** This is a self-report questionnaire designed to assess the degree of enjoyment and satisfaction experienced by individuals across various life domains, such as physical health, mood, work, household duties, social activities, leisure activities, and general well-being. Higher scores indicate greater enjoyment and satisfaction.

**Medical Outcomes Study (MOS) Short-Form General Health Survey (SF-20):** This is another self-report questionnaire that measures general health status across six key dimensions: physical functioning, role functioning (limitations due to physical health), social functioning, mental health, health perceptions, and bodily pain. Higher scores generally indicate better health and functioning.

The study also assessed the relationship between improvement in QoL and improvement in depression symptoms, suggesting that depression symptom reduction was a secondary outcome or a covariate of interest.

The study included a total of **96 patients**.

All participants met strict diagnostic criteria for **Seasonal Affective Disorder (SAD)**. This means they experienced recurrent episodes of major depression that typically begin in the fall or winter and remit in the spring, for at least two consecutive years, without non-seasonal depressive episodes.

The study was conducted in **Canada** and was a **multicentre trial**, meaning participants were recruited from multiple clinical sites across the country. This approach helps to ensure that the findings are not specific to a single clinic or geographic location, increasing the generalizability of the results to a broader SAD population. The abstract does not specify age range, gender distribution, or other demographic details, but the focus was exclusively on individuals formally diagnosed with SAD.

Quality of life (QoL) was measured using two standardized, self-report questionnaires:

1. **Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q):** This instrument asks individuals to rate their level of enjoyment and satisfaction across a wide range of daily activities and life domains over the past week. These domains typically include physical health, mood, work/school, household activities, social life, leisure activities, and general sense of well-being. The abstract reports average scores, suggesting a total score is derived from summing or averaging responses across these domains. A higher score on the Q-LES-Q indicates greater enjoyment and satisfaction with life. The abstract provides baseline and 8-week scores, indicating its use as a measure of change over time.

2. **Medical Outcomes Study (MOS) Short-Form General Health Survey (SF-20):** This questionnaire assesses an individual's perception of their general health status. It covers six key dimensions:

* **Physical Functioning:** How much health limits physical activities.

* **Role Functioning:** How much physical health interferes with work or daily activities.

* **Social Functioning:** How much physical or emotional problems interfere with social activities.

* **Mental Health:** Feelings of nervousness, depression, calm, happiness.

* **Health Perceptions:** General feelings about one's health.

* **Bodily Pain:** Severity and impact of pain.

Like the Q-LES-Q, the SF-20 is a self-report measure, and higher scores generally indicate better health and functioning in the respective domains.

Both questionnaires were administered at **baseline** (before treatment began) and again at **8 weeks** (at the end of the treatment period) to assess changes in QoL over the course of the intervention. The use of two distinct QoL measures provides a more comprehensive assessment and helps to ensure that the findings are robust, as different scales might capture slightly different aspects of well-being.

This study was a **double-blind, multicentre, randomized controlled trial (RCT)**. This is considered the gold standard for clinical research because it minimizes bias and allows for strong conclusions about cause and effect.

**Study Design and Randomization:**

**Randomized Controlled Trial (RCT):** Patients diagnosed with SAD were randomly assigned to one of two treatment groups. Randomization is crucial because it helps ensure that, on average, the groups are similar in all characteristics (known and unknown) at the start of the study. This means any differences observed at the end of the study are more likely due to the treatment itself rather than pre-existing differences between the groups.

**Multicentre:** The study was conducted across multiple clinical sites in Canada. This enhances the generalizability of the findings, as it suggests the results are not unique to a specific clinic's patient population or practices.

**Blinding:**

**Double-blind:** This means that neither the patients nor the researchers (including those administering treatments and assessing outcomes) knew which treatment each patient was receiving.

* For the light therapy, this was achieved by providing a 10,000 lux light box to one group and a 100 lux light box (acting as a placebo light) to the other. While 100 lux is still light, it is significantly less intense than 10,000 lux and is generally considered insufficient to treat SAD, thus serving as an active placebo.

* For the medication, one group received 20 mg fluoxetine capsules, while the other received identical-looking placebo capsules.

* The combination of 10,000 lux light with a placebo capsule, and 100 lux light with a fluoxetine capsule, ensured that both patients and researchers were unaware of the active treatment component. This double-blinding is critical for minimizing **observer bias** (where researchers' expectations might influence their assessment) and **participant bias** (where patients' expectations might influence their self-reported outcomes).

**Duration:**

The treatment period lasted **8 weeks**. QoL measures were taken at baseline and again at the end of the 8-week period. This duration is common in SAD treatment studies and is generally considered sufficient to observe a therapeutic response to both light therapy and antidepressant medication.

**Statistical Approach:**

The abstract states that both intervention groups showed "significant improvement" in QoL over time and that "no significant differences" were detected by treatment condition. This implies that appropriate statistical tests (e.g., repeated measures ANOVA or mixed-effects models for changes over time, and t-tests or ANOVA for group comparisons) were used to determine the probability that the observed changes or differences occurred by chance. A "significant" finding typically means the p-value was below a predetermined threshold (e.g., p < 0.05). The strong association between QoL improvement and depression symptom improvement suggests correlational analyses were also performed.

**What this design can and cannot prove:**

**Can Prove:** As an RCT, this study can establish a **causal relationship** between the treatments (10,000 lux light therapy or 20 mg fluoxetine) and improvements in quality of life for patients with SAD. The double-blinding strengthens this by minimizing psychological effects and biases. The multicentre nature suggests the findings are likely **generalizable** to a broader population of SAD patients.

**Cannot Prove:**

* **Superiority over no treatment:** Because both groups received an "active" intervention (either 10,000 lux light or 100 lux light plus fluoxetine), the study cannot definitively conclude whether *any* light therapy or fluoxetine is better than *no* treatment at all. The 100 lux light served as a placebo for the light therapy arm, but it is still a form of light exposure.

* **Long-term effects:** The 8-week duration is relatively short. The study cannot provide information on the sustained effects of these treatments beyond this period, nor can it assess potential long-term side effects or the need for continued treatment.

* **Optimal dosing or timing:** While it tested specific doses (10,000 lux, 20 mg fluoxetine), it doesn't explore whether higher/lower doses or different schedules might be more effective or have fewer side effects.

* **Effectiveness in non-SAD populations:** The findings are specific to individuals diagnosed with SAD and cannot be extrapolated to people with other forms of depression or general population without SAD.

**Major Methodological Weaknesses:**